
CHEK2 riskScore Clinical Scenario – High Risk
A 41-year-old woman without a personal history of cancer presents to her provider to better understand her risk of breast cancer.
A 41-year-old woman without a personal history of cancer presents to her provider to better understand her risk of breast cancer.
A 41-year-old woman without a personal history of cancer presents to her provider to better understand her risk of breast cancer.
A healthy 37-year-old woman approaches her doctor because she is concerned about her risk of breast cancer.
Cost should never be a barrier when patients need genetic testing. That’s why it’s Myriad’s promise to make testing accessible and affordable. For patients
Why is Variant Reclassification in Hereditary Cancer Testing Important? Variant classification is a key component of germline testing, allowing patients to have an accurate answer
High and moderate penetrant genes, such as BRCA1, BRCA2, PALB2, CHEK2, and ATM, account for approximately 25% of familial breast cancer risk.
In my new role as Senior Vice President of Medical Affairs of Myriad Oncology, I want to be completely accessible to our providers. Because of
Myriad’s riskScore helps to refine a woman’s risk of breast cancer, with or without a family history of breast cancer.
We are heartbroken over the systemic discrimination and racism that have persisted in this nation for too long. We have been quiet in reflection but
Hosted by Dr. Thomas Slavin, Senior Vice President of Medical Affairs for Myriad Oncology, Inside the GENOME is a casual, educational podcast exploring the world